3 lectures · 99 items
Stroke Insights – Connecting science and lived experience
Heart failure is common in people with atrial fibrillation detected during screening
Stroke identified as the second leading cause of death from cardiovascular disease and a major contributor of acquired long-term disability
PCSK9 Inhibitor Prevents First Heart Attack or Stroke in High-Risk PatientsSlides | Update on stroke prevention in atrial fibrillationUpdate on stroke prevention in atrial fibrillationLower extremity artery disease: a neglected major CV disease
Погоджена настанова EPCCS щодо профілактики інсульту при фібриляції передсердь в системі надання первинної медичної допомоги
EPCCS consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary careThis Circulation review addresses the growing population of Kawasaki disease survivors at risk for acute coronary syndrome, highlighting how KD-specific coronary pathology and thrombosis risk diverge…
A COMBINE-AF Analysis.
A pooled analysis of five pivotal randomized trials (COMBINE-AF; n=73,737) demonstrates that extracranial bleeding occurs in 26% of patients with atrial fibrillation on oral anticoagulants over a…
the safety and efficacy of oral anticoagulants in atrial fibrillation patients with prior intracranial haemorrhage: a systematic review and meta-analysis.
A systematic review and meta-analysis evaluated direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation and a history of intracranial haemorrhage…
milvexian prevents no events after an acute coronary syndrome and does not bleed less, a blow to the factor XI hypothesis in ACS
The full results of the trial stopped for futility in November 2025: 14,194 patients within 7 days of an ACS with at least two risk factors, milvexian 25 mg twice daily or placebo on top of…
the hypothesis, the promise and the LIBREXIA ACS lesson
Factor XI inhibition promises antithrombotic effect without the bleeding cost, but the field keeps hitting reality: after asundexian, the 14,000-patient LIBREXIA ACS trial of milvexian was halted for…
A recent narrative review synthesizes evidence on antithrombotic management in patients with stable chronic coronary syndrome (CCS) and atrial fibrillation (AF). Trials including AFIRE, EPIC-CAD…
Care pathways in atrial fibrillation (AF) are poorly characterised and may influence guideline-concordant treatment. In the Optum database (37,370 patients with incident AF, 2015–2023), 20.6% had a…
An ASPERA-R Inverse Probability Weighted Analysis.
Sex-specific outcomes after breakthrough ischaemic stroke on oral anticoagulation (OAC) in atrial fibrillation were unknown. In the international retrospective ASPERA-R study (1,649 patients, 52%…
the VISION Cardiac Surgery cohort.
In the prospective VISION Cardiac Surgery cohort (12,234 patients, 12 countries), new-onset postoperative atrial fibrillation (POAF) occurred in 31.8% within 30 days of cardiac surgery…
Cerebral amyloid angiopathy (CAA) — deposition of beta-amyloid in the brain's small vessels — is a major cause of haemorrhagic stroke and contributes to cognitive decline and to complications of…
Prospective cohort study at Sahlgrenska University Hospital in 314 patients with Takotsubo syndrome (TS, n=68), anterior STEMI (n=148), or non-anterior STEMI (n=98), with serial echocardiography on…
Multinational cohort study (UK EHR + Quebec claims, 2011-2020) in 30,240 patients with nonvalvular atrial fibrillation initiating concomitant DOAC and NSAID (37,833 episodes; 45.2% COX-2-selective…
